Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

AV-101 reverses L-Dopa-induced dyskinesia in parkinsonian monkeys

Sep. 22, 2020

Phase Ib data for DNL-201 in patients with PD with and without LRRK2 mutations

Sep. 22, 2020

Ensysce Biosciences discloses new compounds for ADHD

Sep. 22, 2020

New antibody-mediated multiple sclerosis model developed

Sep. 21, 2020

SAGE-718 studied in phase II for Parkinson's disease mild cognitive impairment

Sep. 21, 2020

Athira opens enrollment in phase II trial of ATH-1017 for mild to moderate Alzheimer's

Sep. 21, 2020

HSG and Prilenia partner on phase III study of pridopidine in Huntington's disease

Sep. 18, 2020

Animal model shows potential of fluvoxamine for non-motor Parkinson's disease symptoms

Sep. 18, 2020

Eisai presents compounds for cognitive disorders

Sep. 18, 2020

Autobahn Therapeutics synthesizes new TR-beta agonists

Sep. 18, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 21, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...